Akero Therapeutics Financials
This page shows Akero Therapeutics (AKRO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Akero Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Akero Therapeutics passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Akero Therapeutics reported a net loss of $252.1M while operations used $230.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Akero Therapeutics reported an operating loss of $285.4M against $4.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Akero Therapeutics's EBITDA was -$285.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 65.1% from the prior year.
Akero Therapeutics reported -$252.1M in net income in fiscal year 2024. This represents a decrease of 66.1% from the prior year.
Akero Therapeutics earned -$3.75 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 29.8% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Akero Therapeutics held $340.2M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Akero Therapeutics paid $0.00 per share in dividends in fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Akero Therapeutics's ROE was -33.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 5.3 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Akero Therapeutics invested $247.5M in research and development in fiscal year 2024. This represents an increase of 74.5% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
AKRO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $78.9M+13.9% | $69.3M-0.4% | $69.6M | N/A | $72.2M+30.6% | $55.3M+9.2% | $50.6M | N/A |
| SG&A Expenses | $11.4M-2.3% | $11.6M+2.7% | $11.3M | N/A | $9.5M-9.1% | $10.4M+12.0% | $9.3M | N/A |
| Operating Income | -$90.2M-11.6% | -$80.9M0.0% | -$80.9M | N/A | -$81.7M-24.3% | -$65.7M-9.7% | -$60.0M | N/A |
| Interest Expense | $1.1M-6.8% | $1.2M+1.6% | $1.2M | N/A | $1.2M+1.2% | $1.2M+24.2% | $991K | N/A |
| Net Income | -$81.6M-15.7% | -$70.5M+0.3% | -$70.7M | N/A | -$72.7M-29.9% | -$56.0M-5.0% | -$53.3M | N/A |
| EPS (Diluted) | -$0.99-15.1% | -$0.86+4.4% | -$0.90+9.1% | -$0.99+5.7% | -$1.05-29.6% | -$0.81+10.0% | -$0.90+11.8% | -$1.02 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
AKRO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B-9.3% | $1.1B-4.0% | $1.2B+40.0% | $825.9M+1.0% | $817.5M-5.5% | $865.0M-5.2% | $912.2M+57.2% | $580.3M |
| Current Assets | $754.5M-1.3% | $764.6M+7.2% | $713.2M-7.4% | $770.4M+3.1% | $746.9M-3.8% | $776.0M-14.8% | $911.3M+62.7% | $560.0M |
| Cash & Equivalents | $176.0M-20.1% | $220.4M+18.6% | $185.9M-45.4% | $340.2M+7.6% | $316.1M+1.8% | $310.4M-50.3% | $623.9M+166.4% | $234.2M |
| Total Liabilities | $47.9M-42.5% | $83.3M+15.7% | $72.0M-5.0% | $75.8M-4.4% | $79.2M+18.3% | $67.0M+1.5% | $66.0M+46.8% | $45.0M |
| Current Liabilities | $47.7M-21.1% | $60.4M+42.3% | $42.4M+6.8% | $39.8M-8.2% | $43.3M+38.9% | $31.2M+3.0% | $30.3M+58.2% | $19.1M |
| Total Equity | $957.6M-6.6% | $1.0B-5.4% | $1.1B+44.5% | $750.1M+1.6% | $738.3M-7.5% | $798.1M-5.7% | $846.3M+58.1% | $535.3M |
| Retained Earnings | -$1.0B-8.4% | -$967.4M-7.9% | -$896.9M-8.6% | -$826.2M-9.3% | -$756.1M-10.6% | -$683.4M-8.9% | -$627.4M-9.3% | -$574.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AKRO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$67.2M-39.2% | -$48.2M+28.7% | -$67.7M-0.9% | -$67.1M+4.7% | -$70.4M-22.6% | -$57.5M-63.5% | -$35.1M+27.7% | -$48.6M |
| Investing Cash Flow | $56.8M-28.4% | $79.3M+116.5% | -$482.2M-3257.3% | $15.3M-79.1% | $73.1M+128.6% | -$255.9M-542.4% | $57.8M+352.4% | $12.8M |
| Financing Cash Flow | -$34.0M-1091.2% | $3.4M-99.1% | $395.5M+420.5% | $76.0M+2377.7% | $3.1M+2144.7% | -$150K-100.0% | $366.9M+72995.2% | $502K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AKRO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -8.5%-1.7pp | -6.9%-0.3pp | -6.5% | N/A | -9.8%-2.8pp | -7.0%-0.7pp | -6.3% | N/A |
| Return on Assets | -8.1%-1.8pp | -6.4%-0.2pp | -6.1% | N/A | -8.9%-2.4pp | -6.5%-0.6pp | -5.9% | N/A |
| Current Ratio | 15.83+3.2x | 12.66-4.1x | 16.80-2.6x | 19.38+2.1x | 17.25-7.6x | 24.89-5.2x | 30.12+0.8x | 29.27 |
| Debt-to-Equity | 0.050.0x | 0.080.0x | 0.070.0x | 0.100.0x | 0.110.0x | 0.080.0x | 0.080.0x | 0.08 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Akero Therapeutics Ranks
Frequently Asked Questions
Is Akero Therapeutics profitable?
No, Akero Therapeutics (AKRO) reported a net income of -$252.1M in fiscal year 2024.
What is Akero Therapeutics's EBITDA?
Akero Therapeutics (AKRO) had EBITDA of -$285.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Akero Therapeutics's return on equity (ROE)?
Akero Therapeutics (AKRO) has a return on equity of -33.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Akero Therapeutics's operating cash flow?
Akero Therapeutics (AKRO) recorded an outflow of $230.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Akero Therapeutics's total assets?
Akero Therapeutics (AKRO) had $825.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Akero Therapeutics spend on research and development?
Akero Therapeutics (AKRO) invested $247.5M in research and development during fiscal year 2024.
What is Akero Therapeutics's current ratio?
Akero Therapeutics (AKRO) had a current ratio of 19.38 as of fiscal year 2024, which is generally considered healthy.
What is Akero Therapeutics's debt-to-equity ratio?
Akero Therapeutics (AKRO) had a debt-to-equity ratio of 0.10 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Akero Therapeutics's return on assets (ROA)?
Akero Therapeutics (AKRO) had a return on assets of -30.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does Akero Therapeutics's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, Akero Therapeutics (AKRO) held $797.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $230.1M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Akero Therapeutics's Piotroski F-Score?
Akero Therapeutics (AKRO) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Akero Therapeutics's earnings high quality?
Akero Therapeutics (AKRO) reported a net loss of $252.1M while operations used $230.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Akero Therapeutics cover its interest payments?
Akero Therapeutics (AKRO) reported an operating loss of $285.4M against $4.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.